What does SymBio Pharmaceuticals Limited do?

SymBio Pharmaceuticals Limited (SYMQY) operates in the Medical - Pharmaceuticals industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is SYMQY's market cap?

SymBio Pharmaceuticals Limited (SYMQY) has a market capitalization of approximately $26.4 million, as of August 25, 2026, based on the most recent share price and shares outstanding.

Does SYMQY pay a dividend?

No — SymBio Pharmaceuticals Limited (SYMQY) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

SymBio Pharmaceuticals Limited (SYMQY) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

SYMQY

SymBio Pharmaceuticals Limited

OTC·Medical, Pharmaceuticals · Healthcare

$0.56$0.00+0.00%

Market cap$26.38M·Market closed·Aug 25 8:00 PM UTC

Price Chart

$0.56+$0.00 (+0.00%)today

−77.23%CAGR −25.62%

Select date range

FromTo

Aug 5, 2016Aug 27, 2021 → Aug 27, 2026· 5.0 yrsAug 27, 2026

Key Metrics

SYMQY does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings DateOct 29

Last Report DateAug 10

Reported vs Estimate−$0.09

Earnings Surprise—

FinancialsFinancials Tab

Revenue¥1.14B

Net Income−¥6.11B

Net Margin−533.9%

Operating Cash Flow¥0.00

Capital Expenditures¥0.00

Free Cash Flow¥0.00

Return on Equity—

Return on Invested Capital−508.2%

Net Cash¥143.73M

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for SYMQY and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how SYMQY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for SYMQY and 80,000+ other tickers.

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Ltd. engages in the pharmaceutical business. It researches, develops, manufactures, and sells new drugs focusing on the areas of oncology, hematology, and autoimmune diseases. The company was founded by Fuminori Yoshida on March 25, 2005 and is headquartered in Tokyo, Japan.

CEO: Fuminori Yoshida
Sector: Healthcare
Industry: Medical - Pharmaceuticals
Exchange: OTC
Employees: 91
Website: www.symbiopharma.com

Peers

Peers Tab

GDNSF

Goodness Growth Holdings, Inc.

Elegance Optical International Holdings Limited

Cap

$63.4M

Latest News

News Tab

No recent news available.

Frequently Asked Questions About SYMQY

What does SymBio Pharmaceuticals Limited do?: SymBio Pharmaceuticals Limited (SYMQY) operates in the Medical - Pharmaceuticals industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is SYMQY's market cap?: SymBio Pharmaceuticals Limited (SYMQY) has a market capitalization of approximately $26.4 million, as of August 25, 2026, based on the most recent share price and shares outstanding.
Does SYMQY pay a dividend?: No — SymBio Pharmaceuticals Limited (SYMQY) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is SYMQY profitable?: SymBio Pharmaceuticals Limited (SYMQY) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.